Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Janssen Vaccines

Biotech & Life Sciences · Leiden, Netherlands · Founded 2000 · IPO 2000 Unicorn

Vaccine development and manufacturing using proprietary platforms

Investors

2 investors on Janssen Vaccines's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 1 investor entered at this stage
Series B+ 1 investor entered at this stage
Leiden University

Global footprint

Where Janssen Vaccines has talent and traffic

Workforce by country
🇳🇱 Netherlands · Leiden HQ
Book a demo for the full country breakdown
Web traffic by country
33K monthly visits
across markets
🇺🇸 United States80.3%
🇵🇱 Poland18.2%
🇨🇦 Canada0.9%
Top 3 markets shown

Patent intelligence

$7.1B patent portfolio · 3,963 active families

Estimated portfolio value
$7.1B
27.9× the top peer Zealand Pharma ($254M)
3,963 active patent families
Where Janssen Vaccines innovates Biomedical engineeringTGE VACCINEMolecular biologyVirosomePharmaceutical Substances

Where Janssen Vaccines concentrates vs peers

Each axis is a top-10 topic across Janssen Vaccines and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Janssen Vaccines

An AI-synthesized read of the highest-engagement posts about Janssen Vaccines on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Janssen Vaccines on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.